From: Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates
Modifier
Log-OS HRs
Log-PFS HRs
AIC
R2
Cancer type
-8.134
46%
51.85
37%
Therapeutic agent(s)
22.17
0%
65.08
12%
Type of masking
-30.38
27%
45.8